Nonvalvular atrial fibrillation: Evidence for a prothrombotic state

CMAJ. Canadian Medical Association Journal

Volumn 157, Issue 6, 1997, Pages 673-681

  Kahn, Susan R ^a   Solymoss, Susan ^a,b,c   Flegel, Kenneth M ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c Royal Victoria Hospital

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE A; HEMOGLOBIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EMBOLISM; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEMOGLOBIN DETERMINATION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SINUS RHYTHM; STROKE; TEACHING HOSPITAL; THROMBOCYTE COUNT; THROMBOSIS;

EID: 0030818521     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978;28:973-7.
2. Tanaka H, Hayashi M, Date C, Imai K, Asada M, Shoji H, et al. Epidemiologie studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke 1985;16:773-80.
3. Flegel KAI, Shipley MJ, Rose G. Risk of stroke in nonrheumadc atrial fibrillation. Lancet 1987;l:526-9.
4. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-39.
5. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175-9.
6. Connolly SJ, Laupaucis A, Gent AI, Roberts RS, Cairns JA, Joyner C, and the CAFA Study Co-investigators. Canadian Atrial Fibrillation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
7. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
8. Ezekowitz MD, Bridgets SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
9. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann InteniMcJl992;ll6:l-5.
10. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with non-rheumatic atrial fibrillation: 3 case-control study. Am J MeJ 1991;91: 156-61.
11. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Ann Intent Med 1992;116:6-12.
12. Kannel WB, Abbott RD, Savage DD, McNamara PAI. Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J 1983;106:38996.
13. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Strate 1985;16:I82-8.
14. Hardisty RM, MacPherson JC. One-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Tbromb Diath Haemorrb 1962;7:215-29.
15. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. AaaHematobgica (Basel) 1957;17:237.
16. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. AnalBiocbem 1966;15:45-52.
17. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982;59:I086-97.
18. Fiore, L, Deykin, D. Anticoagulant therapy. In: Beutler E, Lichtman M, Coller B, Kipps T, editors. Williams bematology. 5th ed. New York: MccGraw Hill; 1995. p. 1567-8.
19. Williams, WJ, Morris, MW, Nelson, DA. Examination of the blood. In: Beutler E, Lichtman M, Coller B, Kipps T, editors. Williams hematologp. 5th ed. New York: McGraw Hill; 1995. p. 9,14.
20. Bauer KA, Weiss LAI, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. J Clin Invest 1987;80:1527-34.
21. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Tbromb Hemost 1995;73(I):82-6.
22. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990;21:47-51.
23. Lip GYH, Lowe GDO, Dunn FG. Endothelial dysfunction aiW thrombogenesis in atrial fibrillation [abstract]. Ear Heart J 1994;15(suppl):298.
24. Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Hemost 1996;75:219-23.
25. Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. Int Angiol 1992;11:298-303.
26. Nagao T, Hamamoto M, Kanda A, Tsuganesawa T, Ueda M, Kobayashi K, et ai. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with atrial fibrillation. Stroke 1995;26: 1365-8.
27. Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke 1991;22:12-6.
28. Wilhelmsen L, Sva'rdsudd K, Korsan-Bengsten K, Larsson B, WeIin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N EnglJMeJ 1998 11:501-5.
29. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, et al. Haemostatic function and ischémie heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;1:533-7.
30. Thompson SG, Kienast J, Pyke SDAI, Haverkate F, van de Loo JCW. Ilemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
31. Fowkes FGR, Löwe GDO, Housley E, Rattray A, Rumley A, Elton RA, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993;342:84-6.
32. Tohgi H, Yamanouchi H, Murakami M, Kameyama M. Importance of the hematocrit as a risk factor in cerebral infarction. Stroke 1978;9:369-74.
33. Coull BAI, Beamer N, de Garmo P, Sexton G, Nordt F, Knox R, et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischémie attack, and risk factors for stroke. Stroke 1991;22:162-8.
34. Harrison MJG, Pollock S, Kendall BE, Marshall J. Effect of hematocrit on carotid stenosis and cerebral infarction. Lancet 198I;2:114-5.
35. Turritto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980;207:541-3.
36. Thomas DJ, Marshall J, Russell RW, Wetherley-AIein G, du Boulay GH, Pearson GH, et al. Effect of hematocrit on cerebral bloodflow in man. Lancet I977;2:941-3.
37. Yudelman LM, Nossel HL, Kaplan KL, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978;51:1189-95.
38. Eisenberg P, Sherman L, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopepride A: a marker of acute coronary thrombosis. Circulation 1985;71: 912-8.
39. Landi G, Barbarotto R, Morabito A, D'Angelo A. Prognostic significance of fibrinopeptide A in survivors of cerebral infarction. Stroke 1990;21:424-7.
40. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood I987;70(2):343-50.
41. Bauer KA. Prothrombin fragment Fl+2. In: Beutler E, Lichtman M, Coller B, Kipps T, editors. Williams bematolog. 5th ed. New York: McGraw Hill; 1995. p. L98.
42. Toghi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke 1990;21:1663-7.
43. Fon EA, Mackey A, Coté R, Wolfson C, McIlraith DAI, Leclerc J, Bourque F. Hemostatic markers in acute transient ischémie attacks. Stroke 1994;25: 282-6.
44. Dunne JW, Silbert PL, Cannell P. Procoagulant states and stroke [letter]. Stroke 1991;22:1086.